Phenotypic analyses revealed that anti-cancer treatments increased the proportion of effector memory T cells in tumor-infiltrating lymphocytes and splenocytes, and RT in combination with anti-VEGF and anti-PD-L1 therapies, further increased the proportion of central memory T cells in splenocytes. The gene discussed is CD274; the disease is cancer.